New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2012
09:29 EDTABT, RIGLRigel Pharmaceuticals price target lowered to $8 from $15 at Roth Capital
Roth Capital lowered its target on Rigel after the company's rheumatoid arthritis treatment fostamatinib did not demonstrate equivalence versus Abbott's (ABT) Humira in a Phase II test. The firm reduced its estimates for fostamatinib but maintains a Buy rating on the stock based on valuation.
News For RIGL;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
11:19 EDTABTAbbott board increases quarterly dividend to 24c from 22c
The board of Abbott increased the company's quarterly common dividend to 24c per share from 22c per share. The cash dividend is payable Feb. 13, 2015, to shareholders of record at the close of business on Jan. 15, 2015.
December 11, 2014
05:24 EDTABTAbbott IRIDICA now available in Europe
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use